EGFR and metastatic neoplasm: The use of Cetuximab, a monoclonal antibody targeting the extracellular ligand binding domain of the epidermal growth factor receptor (EGFR), combined with radiotherapy is approved for the treatment of locoregionally advanced HNC [19], and for the treatment of recurrent or metastatic disease in combination with platinum-based chemotherapy [20].